Ocugen Raises $115M in Convertible Notes to Repay Debt, Fund Growth
Event summary
- Ocugen plans to raise $115M via convertible senior notes due 2034, with an option for an additional $15M.
- Proceeds will repay $32.7M in debt to Avenue Capital Group affiliates and fund general corporate purposes.
- Notes rank senior to future subordinated debt but junior to secured indebtedness.
- Offering is subject to market conditions and targeted at qualified institutional buyers under Rule 144A.
The big picture
Ocugen's $115M convertible note offering reflects a strategic pivot to strengthen its balance sheet amid high cash burn in biotech development. The move aligns with industry trends of non-dilutive financing to extend runway while maintaining flexibility for future growth initiatives. The deal size underscores investor confidence in Ocugen's pipeline despite broader market headwinds in the gene therapy sector.
What we're watching
- Debt Management
- Whether Ocugen can effectively deploy the remaining proceeds to accelerate its gene therapy pipeline.
- Market Conditions
- How broader market volatility may impact the completion or terms of the offering.
- Dilution Risk
- The potential dilution impact on existing shareholders if notes are converted into common stock.
Related topics